Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: Results from the GUSTO-III trial

American Heart Journal

Volumn 145, Issue 3, 2003, Pages 515-521

  Al Khatib, Sana M ^a   Stebbins, Amanda L ^a   Califf, Robert M ^a   Lee, Kerry L ^a   Granger, Christopher B ^a   White, Harvey D ^b   Armstrong, Paul W ^c   Topol, Eric J ^d   Ohman, E Magnus ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b GREEN LANE HOSPITAL   (New Zealand)

^c UNIVERSITY OF ALBERTA   (Canada)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; LIDOCAINE; RETEPLASE; SOTALOL; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0037350827     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.170     Document Type: Article

References (32)

1. Newby KH, Thompson T, Stebbins A, et al. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. Circulation 1998;98:2567-73.
2. Volpi A, Cavalli A, Santoro L, et al. Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto Miocardico (GISSI-2) database. Am J Cardiol 1998;82:265-71.
3. Volpi A, Cavalli A, Santoro E, et al. Incidence and prognosis of secondary ventricular fibrillation in acute myocardial infarction: evidence for a protective effect of thrombolytic therapy. Circulation 1990;82:1279-88.
4. Volpi A, Cavalli A, Franzosi MG, et al. One-year prognosis of primary ventricular fibrillation complicating acute myocordial infarction. Am J Cardiol 1989;63:1174-8.
5. Volpi A, Maggioni A, Franzosi MG, et al. In-hospital prognosis of patients with acute myocardial infarction complicated by primary ventricular fibrillation. N Engl J Med 1987;317:257-61.
6. Behar S, Reicher-Reiss H, Shechter M, et al. Frequency and prognostic significance of secondary ventricular fibrillation complicating acute myocardial infarction. Am J Cardiol 1993;71:152-6.
7. Behar S, Kishon Y, Reicher-Reiss H, et al. Prognosis of early versus late ventricular fibrillation complicating acute myocardial infarction. Int J Cardiol 1994;45:191-8.
8. Berger PB, Ruocco NA, Ryan TJ, et al. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treoted with recombinant tissue-type plasminogen activator: results from the Thrombolysis In Myocardial Infarction (TIMI) phase II trial. J Am Coll Cardiol 1993;22:1773-9.
9. Jensen GVH, Torp-Pedersen C, Hildebrandt P, et al. Does in-hospital ventricular fibrillation affect prognosis after myocardial infarction? Eur Heart J 1997;18:919-24.
10. Nicod P, Gilpin E, Dittrich H, et al. Late clinical outcomes in patients with early ventricular fibrillation after myocardial infarction. J Am Coll Cardiol 1988;11:464-70.
11. Tofler GH, Stone PH, Muller JE, et al. Prognosis after cardiac arrest due to ventricular tachycardia or ventricular fibrillation associated with acute myocardial infarction (the MILIS Study). Am J Cardiol 1987;60:755-61.
12. Mont L, Cinca J, Blanch P, et al. Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction. J Am Coll Cardiol 1996;28:1670-6.
13. Eldar M, Sievner Z, Goldbourt U, et al. Primary ventricular tachycardia in acute myocardial infarction: clinical characteristics and mortality. Ann Intern Med 1992;117:31-6.
14. GUSTO-III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-23.
15. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation 1995;91:1659-68.
16. Califf RM, White HD, Van de Werf F, et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. Circulation 1996;94:1233-8.
17. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. J Am Coll Cardiol 1998;31:1175-209.
18. Fiol M, Marrugat J, Bayes A, et al. Ventricular fibrillation markers on admission to the hospital for acute myocardial infarction. Am J Cardiol 1993;71:117-9.
19. International Study of Infarct Survival (ISIS) Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57-66.
20. BHAT Study Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA 1982;247:1707-14.
21. Julian DG, Camm AJ, Frangulin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction. Lancet 1997;349:667-74.
22. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations. Lancet 1997;349:675-82.
23. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide or placeba. N Engl J Med 1991;324:781-8.
24. CAST II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33.
25. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993;270:1589-95.
26. Alexander JH, Granger CB, Sadowski Z, et al. Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. Am Heart J 1999;137:799-805.
27. Hine LK, Laird N, Hewitt P, et al. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 1989;149:2694-8.
28. MacMahon S, Collins R, Peto R, et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA 1988;260:1910-6.
29. Hjalmarson A, Herlitz J, Holmberg S, et al. The Göteborg metoprolol trial: effects on mortality and morbidity in acute myocardial infarction. Circulation 1983;67:1-26-32.
30. Ryden L, Ariniego R, Arnman K, et al. A double-blind trial of metoprolol in acute myocardial infarction: effects on ventricular tachyarrhythmias. N Engl J Med 1983;308:614-8.
31. Norris RM, Barnaby PF, Brown MA, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 1984;2:883-6.
32. Cox JL, Lee E, Langer A, et al. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. CMAJ 1997;156:497-505.